Low-dose parenteral busulfan provides an extended window for the infusion of hematopoietic stem cells in murine hosts

Experimental Hematology

Volumn 35, Issue 9, 2007, Pages 1415-1420

  Hsieh, Matthew M ^a   Langemeijer, Saskia ^a   Wynter, Aisha ^a   Phang, Oswald A ^a   Kang, Elizabeth M ^a,b   Tisdale, John F ^a  

^a NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES   (United States)

^b NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BUSULFAN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; AUTOTRANSPLANTATION; BLOOD CELL COUNT; CONTROLLED STUDY; DNA MODIFICATION; DOSE RESPONSE; DRUG DOSE INCREASE; DRUG INFUSION; HEMATOPOIETIC STEM CELL; LOW DRUG DOSE; MOUSE; NONHUMAN; PRIORITY JOURNAL; WHOLE BODY RADIATION;

ANIMALS; BUSULFAN; DOSE-RESPONSE RELATIONSHIP, DRUG; GRAFT SURVIVAL; HEMATOPOIETIC STEM CELL TRANSPLANTATION; INFUSIONS, PARENTERAL; LEUKOCYTE COUNT; MICE; MICE, INBRED C57BL; PLATELET COUNT; TIME FACTORS;

MURINAE; MUS;

EID: 34548143353     PISSN: 0301472X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.exphem.2007.05.009     Document Type: Article

References (35)

1. Walters M.C., Patience M., Leisenring W., et al. Bone marrow transplantation for sickle cell disease. N Engl J Med 335 (1996) 369-376
2. Woolfrey A.E., Pulsipher M.A., and Storb R. Non-myeloablative hematopoietic cell transplant for treatment of nonmalignant disorders in children. Int J Hematol 76 Suppl 2 (2002) 271-277
3. Storb R.F., Lucarelli G., McSweeney P.A., and Childs R.W. Hematopoietic cell transplantation for benign hematological disorders and solid tumors. Hematology Am Soc Hematol Educ Prog (2003) 372
4. Hacein-Bey-Abina S., Le Deist F., Carlier F., et al. Sustained correction of X-linked severe combined immunodeficiency by ex vivo gene therapy. N Engl J Med 346 (2002) 1185-1193
5. Aiuti A., Slavin S., Aker M., et al. Correction of ADA-SCID by stem cell gene therapy combined with nonmyeloablative conditioning. Science 296 (2002) 2410-2413
6. Ott M.G., Schmidt M., Schwarzwaelder K., et al. Correction of X-linked chronic granulomatous disease by gene therapy, augmented by insertional activation of MDS1-EVI1, PRDM16 or SETBP1. Nat Med 12 (2006) 401-409
7. Heim D.A., Hanazono Y., Giri N., et al. Introduction of a xenogeneic gene via hematopoietic stem cells leads to specific tolerance in a rhesus monkey model. Mol Ther 1 (2000) 533-544
8. Mardiney III M., and Malech H.L. Enhanced engraftment of hematopoietic progenitor cells in mice treated with granulocyte colony-stimulating factor before low-dose irradiation: implications for gene therapy. Blood 87 (1996) 4049-4056
9. Giri N., Kaushiva A., Wu T., Sellers S.E., and Tisdale J.F. The effects of SCF/G-CSF prestimulation on radiation sensitivity and engraftment in nonmyeloablated murine hosts. Exp Hematol 29 (2001) 779-785
10. Kang E., Giri N., Wu T., et al. In vivo persistence of retrovirally transduced murine long-term repopulating cells is not limited by expression of foreign gene products in the fully or minimally myeloablated setting. Hum Gene Ther 12 (2001) 1663-1672
11. Huhn R.D., Tisdale J.F., Agricola B., Metzger M.E., Donahue R.E., and Dunbar C.E. Retroviral marking and transplantation of rhesus hematopoietic cells by nonmyeloablative conditioning. Hum Gene Ther 10 (1999) 1783-1790
12. Kang E.M., Hanazano Y., Frare P., et al. Persistent low-level engraftment of rhesus peripheral blood progenitor cells transduced with the fanconi anemia C gene after conditioning with low-dose irradiation. Mol Ther 3 (2001) 911-919
13. Haddow A., and Timmis G.M. Myleran in chronic myeloid leukaemia; chemical constitution and biological action. Lancet 264 (1953) 207-208
14. Galton D.A. Myleran in chronic myeloid leukaemia; results of treatment. Lancet 264 (1953) 208-213
15. Santos G.W., Tutschka P.J., Brookmeyer R., et al. Marrow transplantation for acute nonlymphocytic leukemia after treatment with busulfan and cyclophosphamide. N Engl J Med 309 (1983) 1347-1353
16. Mauch P., Down J.D., Warhol M., and Hellman S. Recipient preparation for bone marrow transplantation. I. Efficacy of total-body irradiation and busulfan. Transplantation 46 (1988) 205-210
17. Yeager A.M., Shinn C., and Pardoll D.M. Lymphoid reconstitution after transplantation of congenic hematopoietic cells in busulfan-treated mice. Blood 78 (1991) 3312-3316
18. Andersson B.S., Madden T., Tran H.T., et al. Acute safety and pharmacokinetics of intravenous busulfan when used with oral busulfan and cyclophosphamide as pretransplantation conditioning therapy: a phase I study. Biol Blood Marrow Transplant 6 (2000) 548-554
19. Fernandez H.F., Tran H.T., Albrecht F., Lennon S., Caldera H., and Goodman M.S. Evaluation of safety and pharmacokinetics of administering intravenous busulfan in a twice-daily or daily schedule to patients with advanced hematologic malignant disease undergoing stem cell transplantation. Biol Blood Marrow Transplant 8 (2002) 486-492
20. de Lima M., Couriel D., Thall P.F., et al. Once-daily intravenous busulfan and fludarabine: clinical and pharmacokinetic results of a myeloablative, reduced-toxicity conditioning regimen for allogeneic stem cell transplantation in AML and MDS. Blood 104 (2004) 857-864
21. Madden T., de Lima M., Thapar N., et al. Pharmacokinetics of once-daily IV busulfan as part of pretransplantation preparative regimens: a comparison with an every 6-hour dosing schedule. Biol Blood Marrow Transplant 13 (2007) 56-64
22. Kang E.M., Hsieh M.M., Metzger M., et al. Busulfan pharmacokinetics, toxicity, and low-dose conditioning for autologous transplantation of genetically modified hematopoietic stem cells in the rhesus macaque model. Exp Hematol 34 (2006) 132-139
23. Kahl C.A., Tarantal A.F., Lee C.I., et al. Effects of busulfan dose escalation on engraftment of infant rhesus monkey hematopoietic stem cells after gene marking by a lentiviral vector. Exp Hematol 34 (2006) 369-381
24. Elson L.A., Galton D.A., and Till M. The action of chlorambucil (CB. 1348) and busulphan (myleran) on the haemopoietic organs of the rat. Br J Haematol 4 (1958) 355-374
25. Dunn C.D. The chemical and biological properties of busulphan ("Myleran"). Exp Hematol 2 (1974) 101-117
26. Mielcarek M., Sandmaier B.M., Maloney D.G., et al. Nonmyeloablative hematopoietic cell transplantation: status quo and future perspectives. J Clin Immunol 22 (2002) 70-74
27. Georges G.E., and Storb R. Review of "minitransplantation": nonmyeloablative allogeneic hematopoietic stem cell transplantation. Int J Hematol 77 (2003) 3-14
28. Baron F., and Storb R. Allogeneic hematopoietic cell transplantation following nonmyeloablative conditioning as treatment for hematologic malignancies and inherited blood disorders. Mol Ther 13 (2006) 26-41
29. Santos G.W., and Tutschka P.J. Marrow transplantation in the busulfan-treated rat: preclinical model of aplastic anemia. J Natl Cancer Inst 53 (1974) 1781-1785
30. Adams A.B., Durham M.M., Kean L., et al. Costimulation blockade, busulfan, and bone marrow promote titratable macrochimerism, induce transplantation tolerance, and correct genetic hemoglobinopathies with minimal myelosuppression. J Immunol 167 (2001) 1103-1111
31. Anam K., Black A.T., and Hale D.A. Low dose busulfan facilitates chimerism and tolerance in a murine model. Transpl Immunol 15 (2006) 199-204
32. Bauer Jr. T.R., Hai M., Tuschong L.M., et al. Correction of the disease phenotype in canine leukocyte adhesion deficiency using ex vivo hematopoietic stem cell gene therapy. Blood 108 (2006) 3313-3320
33. Malech H.L., and Hickstein D.D. Genetics, biology and clinical management of myeloid cell primary immune deficiencies: chronic granulomatous disease and leukocyte adhesion deficiency. Curr Opin Hematol 14 (2007) 29-36
34. Persons D.A., and Tisdale J.F. Gene therapy for the hemoglobin disorders. Semin Hematol 41 (2004) 279-286
35. Sadelain M., Boulad F., Galanello R., et al. Therapeutic options for patients with severe beta-thalassemia: the need for globin gene therapy. Hum Gene Ther 18 (2007) 1-9